Project information | Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9] | Guidance

Cetuximab for the treatment of advanced non-small cell lung cancer [ID9]

The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended.

Closing date for invited submissions / evidence submission:	TBC
1st appraisal committee meeting:	TBC

Assessment Group / Evidence Review Group:	Liverpool Reviews and Implementation Group
Communications manager:	Alice Law
Project manager:	Lori Farrar
Technical Lead:	Christian Griffiths

Key events during the development of the guidance:

Date	Update
26 August 2022	Discontinued. The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended.
27 September 2012	The Appraisal Committeewere due to meet on Wednesday 13 February 2013to discuss the use of Cetuximab for the treatment of advanced non-small-cell lung cancer. The manufacturer has informed NICE that they have withdrawn their licence application to the EMA. Therefore, this appraisal is currently suspended. Consequently the discussion of this appraisal at the committee meeting on the Wednesday 13 February 2013 has been cancelled.
15 May 2012	Following update from Manufacturer on regulatory timings this appraisal has been rescheduled and the first Appraisal Committee discussion will take place on 13 February 2013.
29 September 2009	Consultees and commentators informed that this appraisal will be delayed following the opinion issued after the July meeting of the Committee for Medicinal Products for Human (CHMP) of the European Medicines Agency (EMEA)
3 June 2008	Schedule updated.
9 March 2008	Consultees and commentators informed that this appraisal will be delayed due to ongoing regulatory discussions with regard to this license extension.

For further information on our processes and methods, please see our CHTE processes and methods manual